An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma

2008 ◽  
Vol 92 (2) ◽  
pp. 149-155 ◽  
Author(s):  
Andrew D. Norden ◽  
Jan Drappatz ◽  
Alona Muzikansky ◽  
Karly David ◽  
Mary Gerard ◽  
...  
Keyword(s):  
Survival Analysis ◽  
Malignant Glioma ◽  
Recurrent Malignant Glioma ◽  
Angiogenic Therapy

scholarly journals Pharmacokinetic and Tumor Distribution Characteristics of Temsirolimus in Patients with Recurrent Malignant Glioma

2007 ◽  
Vol 13 (24) ◽  
pp. 7401-7406 ◽  
Author(s):  
J. G. Kuhn ◽  
S. M. Chang ◽  
P. Y. Wen ◽  
T. F. Cloughesy ◽  
H. Greenberg ◽  
...  
Keyword(s):  
Malignant Glioma ◽  
Distribution Characteristics ◽  
Recurrent Malignant Glioma ◽  
Tumor Distribution

scholarly journals 3D Conformal Radiotherapy and Cisplatin for Recurrent Malignant Glioma

2008 ◽  
Vol 35 (1) ◽  
pp. 57-64 ◽  
Author(s):  
Lauren VanderSpek ◽  
Barbara Fisher ◽  
Glenn Bauman ◽  
David Macdonald
Keyword(s):  
Malignant Glioma ◽  
Malignant Gliomas ◽  
Conformal Radiotherapy ◽  
Maximum Tolerated Dose ◽  
External Beam Radiation ◽  
Recurrent Malignant Glioma ◽  
Beam Radiation ◽  
Fractionated Radiotherapy ◽  
3D Conformal Radiotherapy ◽  
Grade 3

Purpose:To determine the maximum tolerated dose of 3D conformal radiotherapy in combination with Cisplatin for patients with recurrent malignant gliomas.Methods:From 1999-2003, nine patients with recurrent malignant glioma received fractionated radiotherapy and Cisplatin (20 mg/m2/d IV on days 1-5) in a Phase I radiation dose escalation trial. Three sequential dose levels were evaluated: 25 Gy, 30 Gy, and 35 Gy, using 5 Gy fractions. All patients received prior external beam radiation (median dose 59.4 (20-60) Gy) and five patients received prior chemotherapy.Results:Six male and three female patients were enrolled with a median age of 52 years, and a median Karnofsky performance status score of 70. The median re-irradiated tumor volume was 18.9 (0.1-78.5) cm3 and the median follow-up was 8.8 (3.2-31.2) months. One patient (30 Gy/ 6 fractions) experienced medically reversible acute grade 3 toxicity. A second patient (35 Gy/ 7 fractions) experienced acute grade 2 toxicity and histology showed tumor and radiation effect. A third patient (25 Gy/ 5 fractions) experienced late grade 3 toxicity from radiation necrosis. The radiological responses consisted of complete response (1 patient), partial response (1 patient), and stable disease (2 patients). The median overall survival was 8.8 months (95% CI 8.0-9.9), and the median disease free interval was 2.0 months (95% CI 1.4-4.4). Seven patients received chemotherapy following re-irradiation and Cisplatin.Conclusion:The maximum tolerated dose of 3D conformal fractionated radiotherapy was 30 Gy in 6 fractions with low dose Cisplatin, which was well tolerated in terms of acute toxicity for our patient population. This regimen demonstrated only modest efficacy in the treatment of recurrent malignant glioma. Combinations of conformal re-irradiation and other systemic agents may merit investigation. Currently our recommended dose is 30 Gy in 6 fractions for selected patients.

scholarly journals Boron neutron capture therapy with bevacizumab may prolong the survival of recurrent malignant glioma patients: four cases

2014 ◽  
Vol 9 (1) ◽  
Author(s):  
Shin-Ichi Miyatake ◽  
Shinji Kawabata ◽  
Ryo Hiramatsu ◽  
Motomasa Furuse ◽  
Toshihiko Kuroiwa ◽  
...  
Keyword(s):  
Malignant Glioma ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Neutron Capture Therapy ◽  
Recurrent Malignant Glioma ◽  
Boron Neutron Capture

Irinotecan Treatment for Recurrent Malignant Glioma Using an Every-3-Week Regimen

2002 ◽  
Vol 25 (2) ◽  
pp. 204-208 ◽  
Author(s):  
Timothy F. Cloughesy ◽  
Emese Filka ◽  
Gillian Nelson ◽  
Fairooz Kabbinavar ◽  
Henry Friedman ◽  
...  
Keyword(s):  
Malignant Glioma ◽  
Recurrent Malignant Glioma

scholarly journals Boron Neutron Capture Therapy and Add-on Bevacizumab in Patients with Recurrent Malignant Glioma

2021 ◽  
Author(s):  
Motomasa Furuse ◽  
Shinji Kawabata ◽  
Masahiko Wanibuchi ◽  
Hiroyuki Shiba ◽  
Koji Takeuchi ◽  
...  
Keyword(s):  
Malignant Glioma ◽  
Boron Neutron Capture Therapy ◽  
Survival Data ◽  
Neutron Capture ◽  
Radiation Necrosis ◽  
Neutron Capture Therapy ◽  
Recurrent Malignant Glioma ◽  
Primary Glioblastoma ◽  
Boron Neutron Capture ◽  
Grade 3

Abstract Introduction: Boron neutron capture therapy (BNCT) has shown excellent survival data but increases in radiation necrosis against recurrent malignant glioma (MG) in previous studies. We proposed that bevacizumab may reduce radiation injury from BNCT by re-irradiation. We evaluated the efficacy and safety of a combination therapy of BNCT and add-on bevacizumab in patients with recurrent MG.Methods: Patients with recurrent MG were treated with reactor-based BNCT. Treatment with bevacizumab (10 mg/kg) was initiated 1–4 weeks after BNCT irradiation and was re-administered every 2–3 weeks until disease progression. Initially diagnosed glioblastomas were categorized as primary glioblastoma (pGBM) and other forms of MG were categorized as non-pGBM. Results: Twenty-five patients (14 with pGBM and 11 with non-pGBM) were treated with BNCT and add-on bevacizumab. The 1-year survival rate for pGBM and non-pGBM was 63.5% (95% CI, 33.1–83.0) and 81.8% (95%CI, 44.7–95.1), respectively. The median OS was 21.4 months (95% CI, 7.0–36.7) and 73.6 months (95% CI, 11.4–77.2) for pGBM and non-pGBM, respectively (p = 0.0428). The median PFS was 8.3 months (95%CI, 4.2–12.1) and 15.6 months (95% CI, 3.1–29.8) for pGBM and non-pGBM, respectively (p = 0.0207). Alopecia occurred in all patients. Six patients experienced adverse events ≥ grade 3.Conclusions: BNCT and add-on bevacizumab were found to provide both a long OS and a long PFS, compared to the previous studies of BNCT alone for recurrent MG. The add-on bevacizumab may reduce the detrimental effects of BNCT radiation, including pseudoprogression and radiation necrosis.

Recurrent malignant glioma in adults

2002 ◽  
Vol 3 (6) ◽  
pp. 509-524 ◽  
Author(s):  
Stephen B. Tatter
Keyword(s):  
Malignant Glioma ◽  
Recurrent Malignant Glioma

scholarly journals Phase I and Correlative Biology Study of Cilengitide in Patients With Recurrent Malignant Glioma

2007 ◽  
Vol 25 (13) ◽  
pp. 1651-1657 ◽  
Author(s):  
L. Burt Nabors ◽  
Tom Mikkelsen ◽  
Steven S. Rosenfeld ◽  
Fred Hochberg ◽  
Narasimha S. Akella ◽  
...  
Keyword(s):  
Phase I ◽  
Malignant Glioma ◽  
Complete Response ◽  
Maximum Tolerated Dose ◽  
Toxicity Assessment ◽  
Perfusion Magnetic Resonance Imaging ◽  
Hematologic Toxicity ◽  
Recurrent Malignant Glioma ◽  
Time Curve ◽  
Magnetic Resonance Imaging Mri

Purpose This multi-institutional phase I trial was designed to determine the maximum-tolerated dose (MTD) of cilengitide (EMD 121974) and to evaluate the use of perfusion magnetic resonance imaging (MRI) in patients with recurrent malignant glioma. Patients and Methods Patients received cilengitide twice weekly on a continuous basis. A treatment cycle was defined as 4 weeks. Treatment-related dose-limiting toxicity (DLT) was defined as any grade 3 or 4 nonhematologic toxicity or grade 4 hematologic toxicity of any duration. Results A total of 51 patients were enrolled in cohorts of six patients to doses of 120, 240, 360, 480, 600, 1,200, 1,800, and 2,400 mg/m2 administered as a twice weekly intravenous infusion. Three patients progressed early and were inevaluable for toxicity assessment. The DLTs observed were one thrombosis (120 mg/m2), one grade 4 joint and bone pain (480 mg/m2), one thrombocytopenia (600 mg/m2) and one anorexia, hypoglycemia, and hyponatremia (800 mg/m2). The MTD was not reached. Two patients demonstrated complete response, three patients had partial response, and four patients had stable disease. Perfusion MRI revealed a significant relationship between the change in tumor relative cerebral blood flow (rCBF) from baseline and area under the plasma concentration versus time curve after 16 weeks of therapy. Conclusion Cilengitide is well tolerated to doses of 2,400 mg/m2, durable complete and partial responses were seen in this phase I study, and clinical response appears related to rCBF changes.

scholarly journals Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma

2018 ◽  
Vol 23 (8) ◽  
pp. 889 ◽  
Author(s):  
Mary Lou Affronti ◽  
Jennifer Gamboa Jackman ◽  
Frances McSherry ◽  
James E. Herndon ◽  
Elwood C. Massey ◽  
...  
Keyword(s):  
Malignant Glioma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Efficacy And Safety ◽  
Recurrent Malignant Glioma
Sign in / Sign up

Export Citation Format

Share Document